ClinicalTrials.gg
Not yet recruitingNCT05792410Updated Mar 31, 2023

A Phase Ⅰb/Ⅱ Clinical Study of SHR-A1811 Combined With Other Therapies in Patients With HER2 Low Advanced or Metastatic Breast Cancer.

A Phase 1/2 interventional study of SHR-A1811 & Dalpiciclib Isethionate Tablets and SHR-A1811 & Fulvestrant in HER2 Low Advanced or Metastatic Breast Cancer, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Not yet recruiting. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-03-31.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Feb 2024, 2 years 8 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
300
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 52 studies testing trastuzumab rezetecan in Breast Neoplasms — 45 open to participants now, 51 under way, 9 of them phase 3. trastuzumab rezetecan · Breast Neoplasms.

Planned enrollment
10th of 52
300 · median 106
Started
2023
with 8 others
Phase 1/2
7 of 52
6 open now
Primary completion
2024-02
later than 0 of 50 live
Registered
5th of 52
by date
Lead sponsor
8 of 52
Jiangsu HengRui Medicine Co., Ltd.

Among the 52 studies testing trastuzumab rezetecan in Breast Neoplasms, this one is the 10th largest by planned enrollment, is one of 9 that started in 2023, is one of 7 in phase 1/2, reaches primary completion later than 0 of the 50 other live ones, and was the 5th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

45 of the 52 studies testing trastuzumab rezetecan in Breast Neoplasms are open now, in 1 country. Recruiting first, the newest first:

40 more — sign in →

By country, each count listing its studies:

All 45 open studies →

Where they have run

About trastuzumab rezetecan

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years to 75 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies testing trastuzumab rezetecan in Breast Neoplasms, or all of them as a file.
02

Study summary

This study aims to evaluate the safety, tolerability, PK and preliminary anti-tumour activity of SHR-A1811 combined with other therapies in patients with HER2 low advanced or metastatic breast cancer.

03

Conditions studied

  • HER2 Low Advanced or Metastatic Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Ability to give , signed and dated IRB/EC approved informed consent, willing and able to comply with treatment planning visits, tests and other procedural requirements
  2. When signing the informed consent, the age is 18-75 years old (including both ends), female patients who have documented low breast cancer
  3. Performance Status of 0 or 1
  4. Patient must have adequate tumor sample for biomarker assessment
  5. At least one
  6. Adequate organ function

Exclusion criteria

Exclusion Criteria:

  1. There are untreated or active central nervous system (CNS) tumor
  2. There was a third space effusion that could not be controlled by drainage (such as a large number of ascites, pleural effusion and pericardial effusion)
  3. Major surgery within 4 weeks prior to enrollment
  4. Has multiple primary within 5 years, excluding cured basal cell carcinoma of skin, cervical carcinoma in situ, papillary thyroid carcinoma, etc
  5. Has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out at screening
  6. Uncontrolled intercurrent illness
  7. Uncontrolled or significant cardiovascular disease
  8. Has known (HIV) infection, or active or C infection.
  9. According to v5.0 classification, those who have not recovered to grade Ⅰ toxicity caused by previous anti-tumour treatment
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    SHR-A1811 combined with Dalpiciclib Isethionate Tablets

    Drug: SHR-A1811 & Dalpiciclib Isethionate Tablets

  • Experimental
    SHR-A1811 combined with Fulvestrant

    Drug: SHR-A1811 & Fulvestrant

  • Experimental
    SHR-A1811 combined with Bevacizumab injection

    Drug: SHR-A1811 & Bevacizumab injection

Interventions

  • DrugSHR-A1811 & Dalpiciclib Isethionate Tablets

    Drug pages: Trastuzumab rezetecan · Dalpiciclib isethionate

    SHR-A1811:Lyophilized powder injection, 100mg / bottle, intravenous drip Dalpiciclib Isethionate Tablets:Tablet, 25mg / tablet, 50mg / tablet, 125mg / tablet, 150mg / tablet, oral

  • DrugSHR-A1811 & Fulvestrant

    Drug pages: Trastuzumab rezetecan · Fulvestrant

    SHR-A1811:Lyophilized powder injection, 100mg / bottle, intramuscular Fulvestrant:Injection, 5 ml: 0.25g/bottle, intramuscular

  • DrugSHR-A1811 & Bevacizumab injection

    Drug pages: Trastuzumab rezetecan · Bevacizumab

    SHR-A1811:Lyophilized powder injection, 100mg / bottle, intravenous drip Bevacizumab injection: injection, 100mg / bottle, intravenous drip

This study also gives Anastrozole. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. DLT(Phase I (dose-finding phase) main study endpoint)

    Time frame: At the end of cycle 1(each cycle is 28 days for SHR-A1811+ fulvestrant; each cycle is 21 days for SHR-A1811+other therapies.

  2. AE(Phase I (dose-finding phase) main study endpoint)

    Time frame: Up to follow-up period, approximately 24 months

  3. Incidence and severity of serious adverse events (SAE)(Phase I (dose-finding phase) main study endpoint)

    Time frame: Up to follow-up period, approximately 24 months

  4. Objective response rate(The main end points of the second stage (efficacy expansion stage))

    Time frame: Until progression, assessed up to approximately 24 months

Secondary outcomes

  1. SHR-A1811 sparse PK concentrations in serum

    Time frame: While on study drug up to study completion, approximately 24 months

  2. Dalpiciclib sparse PK concentrations in plasm

    Time frame: While on study drug up to study completion, approximately 24 months

  3. Incidence of anti-drug antibodies (ADA) to SHR-A1811 over time

    Time frame: Up to follow-up period, approximately 24 months

  4. Incidence of neutralizing antibody (NAb) to SHR-A1811 over time

    Time frame: Up to follow-up period, approximately 24 months

  5. Duration of response (DoR)

    Time frame: Until progression or death, assessed up to approximately 24 months

  6. Progression-free survival (PFS)

    Time frame: Until progression or death, assessed up to approximately 24 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2023; primary completion for Feb 2024, 10 months later.

Of 161 industry-sponsored phase 1/2 interventional studies under Breast Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 75. This study's planned 10 months is below that.

Counting every sponsor, half of 328 studies reached it within 61 months; a quarter within 45 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 17, 2023
First posted
Mar 31, 2023
StartEst.
Apr 2023
Primary completionEst.
Feb 27, 2024
CompletionEst.
Feb 27, 2025
Last update
Mar 31, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 31, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05792410
Responsible party
Sponsor
First posted
Mar 31, 2023
Start date
Apr 2023 (estimated)
Primary completion
Feb 27, 2024 (estimated)
Completion
Feb 27, 2025 (estimated)
Last update
Mar 31, 2023

Study contacts

Shuchao Wu
Contact
shuchao.wu@hengrui.com.cn
+0518-81220121

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Trastuzumab rezetecan · Dalpiciclib isethionate · Fulvestrant · Bevacizumab

Start the discussion